Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes

[1]  Y. Miyazaki,et al.  [Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes]. , 2013, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[2]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[3]  Z. Estrov,et al.  Final results of the phase II study of rabbit anti‐thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony‐stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome , 2012, British journal of haematology.

[4]  M. Sekeres,et al.  Combination strategies in myelodysplastic syndromes , 2012, International Journal of Hematology.

[5]  G. Ossenkoppele,et al.  Role of immune responses in the pathogenesis of low‐risk MDS and high‐risk MDS: implications for immunotherapy , 2011, British journal of haematology.

[6]  E. Sloand,et al.  Targeting immune dysregulation in myelodysplastic syndromes. , 2011, JAMA.

[7]  A. Ganser,et al.  Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  K. Ishiyama,et al.  Origin and fate of blood cells deficient in glycosylphosphatidylinositol‐anchored protein among patients with bone marrow failure , 2009, British journal of haematology.

[9]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[10]  John Barrett,et al.  Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Kurokawa,et al.  A Prospective Study of Cyclosporine A Treatment of Patients with Low-Risk Myelodysplastic Syndrome: Presence of CD55−CD59− Blood Cells Predicts Platelet Response , 2007, International journal of hematology.

[12]  G. Mufti,et al.  Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin , 2007, Leukemia.

[13]  B. Cheson,et al.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.

[14]  R. Saxena,et al.  Cyclosporin A in myelodysplastic syndrome: a preliminary report , 2005, Annals of Hematology.

[15]  M. Tomonaga,et al.  Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. , 2003, Leukemia research.

[16]  G. Mufti,et al.  A pilot study of antithymocyte globulin (ATG) in the treatment of patients with ‘low‐risk’ myelodysplasia , 2003, British journal of haematology.

[17]  T. Chuhjo,et al.  Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome. , 2002, Blood.

[18]  N. Young,et al.  HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. , 2002, Blood.

[19]  N. Young,et al.  Antithymocyte Globulin for Treatment of the Bone Marrow Failure Associated with Myelodysplastic Syndromes , 2002, Annals of Internal Medicine.

[20]  M. Tomonaga,et al.  Paroxysmal nocturnal haemoglobinuria clones in patients with myelodysplastic syndromes , 1998, British journal of haematology.

[21]  J. Čermák,et al.  Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow , 1998, British journal of haematology.

[22]  N. Young,et al.  Antithymocyte globulin for patients with myelodysplastic syndrome , 1997, British journal of haematology.

[23]  J. G. van den Tweel,et al.  Immunosuppressive therapy for hypoplastic myelodysplastic syndrome , 1997, Cancer.

[24]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[25]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[27]  C. Bloomfield,et al.  The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia : Rationale and Important Changes , 2009 .

[28]  B. Johansson,et al.  Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. , 2006, Haematologica.

[29]  E. Estey,et al.  Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes , 2003, Leukemia.